Device Trial Radar · NCT04221503
Niraparib/TTFields in GBM
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Dec 30, 2019
Primary completion
Jan 2026
Study completion Jan 2026
Sponsor
- Lead sponsor
- Abramson Cancer Center at Penn MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Tesaro, Inc.; NovoCure Ltd.
- First posted
- Jan 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluating the efficacy and safety of niraparib and Tumor-Treating Fields (TTFields) in recurrent glioblastoma (GBM).
Conditions
- Glioblastoma
- Recurrent Glioblastoma
- GBM
Interventions
NiraparibDrug
Niraparib (\[3S\]-3-\[4-{7-(aminocarbonyl)-2H-indazol-2-yl} phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, highly selective poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) -1 and -2 inhibitor. The niraparib drug product is provided as 100-mg capsules filled with a dry blend of niraparib tosylate monohydrate, lactose monohydrate, and magnesium stearate in a hard gelatin capsule.
OptuneDevice
Optune, which is manufactured by Novocure, is a portable battery or power supply operated device which produces alternating electrical fields, called tumor treatment fields ("TTFields") within the human body. TTFields are applied to the patient by electrically-insulated surface transducer arrays. TTFields disrupt the rapid cell division exhibited by cancer cells.
Planned surgical resectionProcedure
Surgery of supratentorial glioblastoma (GBM).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease control, defined as achievement of either CR, PR, or SD, as defined by modified Response Assessment in Neuro-Oncology (mRANO) criteria.Time frame: When termination of the study or 5 years after removal from protocol therapy, whichever occurs first.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.